PaxMedica, Inc. Common Stock
PXMD · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,509 | $393 | $1,165 | $1,939 |
| G&A Expenses | $1,489 | $3,297 | $3,221 | $2,426 |
| SG&A Expenses | $1,489 | $3,297 | $3,221 | $2,426 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $2,999 | $3,690 | $4,386 | $4,365 |
| Operating Income | -$2,999 | -$3,690 | -$4,386 | -$4,365 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$3 | -$1,534 | -$685 |
| Pre-Tax Income | -$2,998 | -$3,693 | -$5,920 | -$5,049 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,998 | -$3,693 | -$5,920 | -$5,049 |
| % Margin | – | – | – | – |
| EPS | -0.39 | -0.5 | -0.8 | -5.2 |
| % Growth | 22% | 37.5% | 84.6% | – |
| EPS Diluted | -0.39 | -0.5 | -0.8 | -5.2 |
| Weighted Avg Shares Out | 7,656 | 7,418 | 7,401 | 972 |
| Weighted Avg Shares Out Dil | 7,656 | 7,418 | 7,401 | 972 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | -$326 |
| EBITDA | -$2,998 | -$3,693 | -$5,920 | -$5,048 |
| % Margin | – | – | – | – |